Q2 2025 Earnings Call Transcript February 28, 2025 Silviu Itescu: Good morning, everybody. I’m Silviu Itescu. I’m the Chief ...

Penn's Dental School and School of Engineering and Applied Science have worked together to create a new treatment option for ...

In an international collaboration, researchers have made an important breakthrough in the therapeutic delivery of microRNAs ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...

Dr. Yvon Woappi, a 2011 University of Pittsburgh at Bradford graduate who researches wound healing and regeneration at his ...

Received FDA authorization to initiate ELEVATE-44-102 in the U.S. –– Received MHRA authorization to initiate ELEVATE-44-201 in the U.K. –– ...

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Intellia's technology platform specializes in Clustered Regularly Interspaced Short ...

This useful study presents findings on the developmental roles of Nup107, a key nucleoporin, in regulating the larval-to-pupal transition in Drosophila melanogaster through its involvement in ecdysone ...

In Regeneron Pharmaceuticals Inc.’s phase I/II Chord study of 12 children with genetic hearing loss tied to the variants of the otoferlin gene, 10 out of 11 have showed notable improvements in their ...

Ever since archaeologists first discovered the ruins of Pompeii – the ancient Roman city buried by the eruption of Mount ...